EMAIL THIS PAGE TO A FRIEND

Cancer research

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.


PMID 28087600

Abstract

Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem from the development of a lymphatic network driven by the production of the main growth factor for lymphatic endothelial cells, VEGFC. In this study, we found that sunitinib can stimulate

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D9760
L-(−)-Dithiothreitol, ≥95%
C4H10O2S2